This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

5-8 November 2024
The Grimaldi ForumMonte Carlo, Monaco

Lucas De Breed
Director, Investments, BrightEdge at American Cancer Society


Dr. de Breed has two decades of experience in Oncology, as a scientist, strategy consultant, VC and entrepreneur.

Previously, as a Manager at Deallus, a global strategy consulting firm for large biopharma clients, he led the Oncology business unit and founded the firm’s East Coast office. As an Investment Director at INKEF Capital, a leading European VC firm, Lucas led the allocation of $120 million in US and European therapeutics start-ups, served on the respective Boards, and realized a number of exits. At INKEF, he was instrumental in setting the investment strategy, building out the investment team and in expanding assets under management to $600 million. He is also the Founder of August, developing outcomes-based financial solutions for high-cost precision medicine.

Dr. de Breed holds a PhD in Molecular Oncology from University College London and an MBA from Stanford University. He has also co-authored several scientific papers. Lucas also serves on the Board of Quantum Leap Healthcare, a 501c(3)charitable organization integrating high-impact clinical research with patient care to improve and save lives.

Agenda Sessions

  • The intersection of impact and health